Navigation Links
Queensland technology licensed by billion-dollar US company
Date:2/15/2008

University of Queensland scientists have developed a proprietary technology that will help other researchers in understanding fundamental aspects of growth, development, and disease, which has been licensed to one of the world's largest life science technology companies.

Dr Marcel Dinger and Professor John Mattick, from UQ's Institute for Molecular Bioscience, have designed a new type of microarray RNA chip, used by researchers to analyse which genes are being expressed at any one time in a particular cell.

The technology has been licensed through IMBcom, UQ's company for the commercialisation of intellectual property arising from research conducted at the IMB. It was licensed to Invitrogen, a provider of essential life science technologies for research, production and diagnostics with a 2006 revenue of US$1.15 billion.

Every cell in the body contains a full set of genes, but different cells express different subsets, Professor Mattick said. In the past these genes were thought only to code mainly for proteins, via the production of "messenger RNAs", but it is now evident that many other genes produce non-coding RNAs whose functions have yet to be determined.

It appears that we have misunderstood the nature of genetic programming in humans and other complex organisms, Professor Mattick said. Most of the genome is transcribed, mainly into non-coding RNAs, which appear to comprise a hidden layer of gene regulation whose full dimensions are just beginning to be explored.

There is increasing recognition that these non-coding RNAs control various levels of gene expression in physiology and development, as well as in the brain.

Products commercialized by Invitrogen will be based on a novel set of RNA probes that Dr Dinger and Professor Mattick have designed, which can uniquely identify tens of thousands of coding and non-coding RNA sequences. This is the first time that one product has been able to identify both large numbers of protein-coding and non-coding RNAs.

This technology will allow researchers to obtain more accurate information about the relationship between messenger and non-coding RNA expression, Dr Peter Isdale, CEO of IMBcom, said. It has the potential to make a real impact in cancer and stem cell research, as these RNAs are implicated in both of these areas.


'/>"/>

Contact: Bronwyn Adams
communications@uq.edu.au
61-733-462-134
Research Australia
Source:Eurekalert

Related medicine news :

1. Fluoridated water for Queensland ... at last
2. Queensland businessman is one in a million
3. QueensLander Tours Presents an Adventure Boot Camp Cruise with John Spencer Ellis from Bravos The Real Housewives of Orange County
4. Quantum light beams good for fast technology
5. New Smart Technology Makes Patient Data Collection Easier, More Efficient
6. Align Technology Executive to Present at Upcoming Financial Conferences
7. Pioneer Surgical Technology Hires Vice President of New Business Development
8. Purdue researchers develop technology to detect cancer by scanning surface veins
9. Creative Technology Services Enhances its Global Competitiveness with Additional Regulatory Certifications
10. University of Wisconsin Hospitals and Clinics Complete System-Wide Conversion to Masimo SET Pulse Oximetry Technology
11. Patent Reform Legislation Threatens Americas Leadership in Medical Technology Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg ... Legal Elite. The attorneys chosen by their peers for this recognition are considered among ... Greenberg Traurig Shareholders received special honors as members of this year’s Legal Elite Hall ...
(Date:6/24/2016)... ... 2016 , ... EB Medicine presented its first-ever “Issue of ... in Ponte Vedra Beach, FL. The awards honor the outstanding work of leading ... and Pediatric Emergency Medicine Practice. , “With this award, we recognize the efforts ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
Breaking Medicine Technology: